Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis.
about
Recent advances in autosomal-dominant polycystic kidney disease.The combination of an HDAC6 inhibitor and a somatostatin receptor agonist synergistically reduces hepato-renal cystogenesis in an animal model of polycystic liver disease.Drug holiday in patients with polycystic liver disease treated with somatostatin analogues
P2860
Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis.
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Alkaline phosphatase predicts ...... ue therapy: a pooled analysis.
@ast
Alkaline phosphatase predicts ...... ue therapy: a pooled analysis.
@en
type
label
Alkaline phosphatase predicts ...... ue therapy: a pooled analysis.
@ast
Alkaline phosphatase predicts ...... ue therapy: a pooled analysis.
@en
prefLabel
Alkaline phosphatase predicts ...... ue therapy: a pooled analysis.
@ast
Alkaline phosphatase predicts ...... ue therapy: a pooled analysis.
@en
P2093
P2860
P356
P1433
P1476
Alkaline phosphatase predicts ...... ue therapy: a pooled analysis.
@en
P2093
Frederik Nevens
Joost P H Drenth
Marie C Hogan
Tom J G Gevers
Vicente E Torres
P2860
P304
P356
10.1111/LIV.12986
P577
2015-10-20T00:00:00Z